• Home
  • Science & Technology
  • Clinical Development
  • Market & Investors
  • Intellectual Property
  • Our Team
  • Contact Us
  • More
    • Home
    • Science & Technology
    • Clinical Development
    • Market & Investors
    • Intellectual Property
    • Our Team
    • Contact Us
  • Home
  • Science & Technology
  • Clinical Development
  • Market & Investors
  • Intellectual Property
  • Our Team
  • Contact Us

Severe Refractory IBS-D: A $2.4 B Addressable Opportunity

High unmet need and significant economic impact position STX-101 to deliver meaningful clinical benefit and capture substantial value

Targeted spend accelerates titration study, digital platform build-out, and regulatory preparation, all within a tightly managed $25 M budget

Copyright © 2025 Serotonix, LLC - All Rights Reserved

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept